After-hours trading on Friday, Evelo Biosciences, Inc. (Nasdaq: EVLO), the stock plunged -11/56% to $10.25. It’s not clear what happened that caused the share price to fall, and investors may want to take that as a warning sign.
A clinical-stage biotechnology company creating new oral medications with systemic effects prioritizes EDP1908 as its lead clinical candidate in oncology.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The Company said that it would cease patient recruitment for Phase 1/2 clinical trial of EDP1503 and finalize the study.
Read More
It revealed on additional interim clinical data from EDP1503, treated with pembrolizumab in TNBC patients with its Phase 1/2 open study, were presented in a poster session at the San Antonio Breast Cancer Symposium (SABCS) 2020 Virtual Meeting. In the 12 patients who received EDP1503 at a higher dose, as of a cutoff date of October 30, 2020, the response rate was 17 percent, with a disease control rate of 25%.
It suggests that the small intestinal axis, SINTAXTM, can be targeted using oral, gut-restricted medicines.
